CXCR4 and acute myeloid leukemia: Previous reports have presented a novel strategy of sensitizing AML cells to cytotoxic chemotherapy using different classes of CXCR4 inhibitors, including AMD3465 [9], LY2510924 [10], BL-8040 [24], ulocuplumab [25], and PF-06747143 [26], some of which are in early phase clinical trials [11].